202529-16-6

202529-16-6 structure

Name: Benztropine-d3 mesylate
Chemical Name: Benztropine-d3 mesylate
CAS Number: 202529-16-6
Molecular Formula: C₂₂H₂₆D₃NO₄S
Molecular Weight: 406.55
Catalog: Signaling Pathways GPCR/G Protein Dopamine Receptor
Create Date: 2023-04-20 21:18:43
Modify Date: 2024-01-02 17:33:52
Benztropine-d3 (mesylate) is the deuterium labeled Benztropine mesylate[1]. Benztropine mesylate (Benzatropine mesylate) is an orally active centrally acting anticholinergic agent that can be used for Parkinson's disease research. Benztropine mesylate is an anti-histamine agent and a dopamine re-uptake inhibitor. Benztropine mesylate is also a human D2 dopamine receptor allosteric antagonist. Benztropine mesylate also has anti-CSCs (cancer stem cells) effects[2][3].

Name	Benztropine-d3 mesylate

Description	Benztropine-d3 (mesylate) is the deuterium labeled Benztropine mesylate[1]. Benztropine mesylate (Benzatropine mesylate) is an orally active centrally acting anticholinergic agent that can be used for Parkinson's disease research. Benztropine mesylate is an anti-histamine agent and a dopamine re-uptake inhibitor. Benztropine mesylate is also a human D2 dopamine receptor allosteric antagonist. Benztropine mesylate also has anti-CSCs (cancer stem cells) effects[2][3].
Related Catalog	Signaling Pathways >> Neuronal Signaling >> mAChR Signaling Pathways >> Immunology/Inflammation >> Histamine Receptor Signaling Pathways >> GPCR/G Protein >> mAChR Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor Signaling Pathways >> GPCR/G Protein >> Histamine Receptor
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [2]. Santosh S Kulkarni, et al. Comparative structure-activity relationships of benztropine analogues at the dopamine transporter and histamine H(1) receptors. Bioorg Med Chem. 2006 Jun 1;14(11):3625-34. [3]. Jihong Cui, et al. New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate. Oncotarget. 2017 Jan 38(1):1007-1022.

Molecular Formula	C₂₂H₂₆D₃NO₄S
Molecular Weight	406.55

202529-16-6	132-17-2
1217860-94-0	1356841-81-0
74195-64-5	6148-20-5
802597-90-6	18164-03-9
1448346-27-7	1111-88-2